Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine
A Phase I Evaluation of the Safety and Immunogenicity of the rDEN1∆30 Dengue Serotype 1 Vaccine Given at a Single Dose of 101 PFU in Healthy Flavivirus-naïve Adult Subjects
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The dengue virus causes approximately 50 million cases of dengue fever and 1.5 million cases of the more severe diseases dengue hemorrhagic fever (DHS) and dengue shock syndrome (DSS) every year. There are four subtypes of the virus, and infection with one offers no protection from infection by the others. In fact, most cases of DHS and DSS occur in people infected by more than one subtype. In areas of the world where multiple subtypes of dengue are common, vaccines must be developed against each of the subtypes of dengue virus. This study will examine the safety and immune response of an investigational vaccine for preventing infection with DEN1.
Participation in this study will last about 6 weeks. Participants will be randomly assigned to be injected with either the investigational study vaccine or a placebo. Participants will have a five in six chance of receiving the vaccine. The first study visit will take place on the vaccination day, on which participants will undergo a physical examination, blood draw, and pregnancy test, and then receive the vaccine. Participants will be given a thermometer and temperature card, and be told to record their temperature three times per day for 16 days after vaccination. Participants will come to follow-up visits every other day for the 16 days after vaccination, and then 3, 4, and 6 weeks after vaccination (Days 21, 28, and 42). Assessments completed during these visits will include a questionnaire about how the participant is feeling, pregnancy test, review of temperature cards, blood draw, and physical exam. Blood drawn will be analyzed to check participants' health, determine the amount of vaccine and antibodies in the blood, test markers in white blood cells and genes, and look for proteins that are important for fighting dengue infection.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05401
- Fletcher Allen Health Care (FAHC) General Clinical Research Center (GCRC)
-
Burlington, Vermont, Estados Unidos, 05401
- University of Vermont Vaccine Testing Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- In good general health as determined by physical examination, laboratory screening, and review of medical history
- Available for the duration of the study, including approximately 6 weeks post-vaccination
- Female participants of childbearing potential must be willing to use effective contraception for the duration of the trial
Exclusion Criteria:
- Currently breast-feeding or pregnant
- Exhibits evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies
- Presence of a behavioral, cognitive, or psychiatric disease that affects the ability of the participant to understand and cooperate with the requirements of the study protocol
- Has screening laboratory values of Grade 1 or above for absolute neutrophil count (ANC), ALT, and serum creatinine, as defined in this protocol
- Presence of any condition that would jeopardize the safety or rights of the participant or would render the participant unable to comply with the protocol
- Significant alcohol or drug abuse in the past 12 months which has caused medical, occupational, or family problems, as indicated by participant history
- History of a severe allergic reaction or anaphylaxis
- Severe asthma (emergency room visit or hospitalization within the last 6 months)
- Presence of HIV infection, determined by screening and confirmatory assays
- Presence of hepatitis C virus (HCV) infection, determined by screening and confirmatory assays
- Presence of hepatitis B virus (HBV) infection, determined by hepatitis B surface antigen (HBsAg) screening
- Presence of any known immunodeficiency syndrome
- Uses anticoagulant medications
- Has used corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 42 days prior to or following vaccination. An immunosuppressive dose of corticosteroids is defined as greater than or equal to 10 mg prednisone equivalent per day for greater than or equal to 14 days.
- Has received a live vaccine within 28 days or a killed vaccine within 14 days prior to vaccination or anticipated receipt of any vaccine during the 42 days following vaccination
- Has no spleen
- Received blood products within the past 6 months, including transfusions or immunoglobulin or anticipated receipt of any blood products or immunoglobulin during the 42 days following vaccination
- History or serologic evidence of previous dengue virus infection or other flavivirus infection (e.g., yellow fever virus, St. Louis encephalitis, West Nile virus)
- Has received a flavivirus vaccine (licensed or experimental)
- Anticipates receipt of any investigational agent in the 42 days before or after vaccination
- Participant has definite plans to travel to a dengue endemic area during the study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: DEN1 Vaccine
Participants will receive a single dose of investigational vaccine for dengue virus subtype 1.
|
Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
Outros nomes:
|
|
Comparador de Placebo: Placebo
Participants will receive a single dose of placebo vaccine.
|
Subcutaneous injection of placebo
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Frequency of vaccine-related adverse events (AEs), as classified by both severity and seriousness, through active and passive surveillance
Prazo: Measured throughout study
|
Measured throughout study
|
|
Immunogenicity to dengue virus subtype one (DEN1), as assessed by neutralizing antibody titers
Prazo: Measured 4 and 6 weeks after vaccination
|
Measured 4 and 6 weeks after vaccination
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Frequency, quantity, and duration of viremia following vaccination
Prazo: Measured every other day after vaccination for 16 days, and on Days 21, 28, and 42
|
Measured every other day after vaccination for 16 days, and on Days 21, 28, and 42
|
|
Number of vaccinees infected with DEN1, defined as recovery of vaccine virus from the blood or serum of a participant and/or by seroconversion to DEN1
Prazo: Measured at study completion
|
Measured at study completion
|
|
Comparison of the infectivity rates, safety, and immunogenicity of a single dose of DEN1 vaccine to those rates of previous clinical trials
Prazo: Measured at study completion
|
Measured at study completion
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Anna Durbin, MD, CIR, Johns Hopkins University
Publicações e links úteis
Publicações Gerais
- Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol. 2006 Spring;19(1):10-32. doi: 10.1089/vim.2006.19.10.
- Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr, Markoff L, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. J Virol. 2003 Jan;77(2):1653-7. doi: 10.1128/jvi.77.2.1653-1657.2003.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CIR 253
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .